Genmab A/S (GMAB)
GMABNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$54.15
-1.65 (-2.96%) today
Regular session, Nov 10, 3:57 PM ET
- Market cap
- $33.78bn
- P/E
- 41.6
- EPS, last 4 quarters
- $1.30
- Dividend yield
- –
- Day range
- $53.15 to $55.23
- 52-week range
- $23.62 to $59.97
- Average volume
- 4.34m
- Previous close
- $55.80
Analysts
11 coveringBuy10 buy, 1 hold, 0 sell
Targets a year out average $64.71, +19.5% from here
Earnings
next estimate $0.2300Next report
Dec 2025
-89.1%
Mar 2026
0.0%
Jun 2026
+46.0%
Sep 2026
+55.6%
estimate reported, and the surprise
Financials
| Quarter | Mar 2019 |
|---|---|
| Revenue | $88.89m |
| Gross profit | $88.89m |
| Operating income | -$3.90m |
| Net income | $10.86m |
News
8 latest- Genmab (GMAB) Q3 2026 Earnings Call TranscriptThe Motley Fool · 4 days ago
- What Genmab A/S (GMAB) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Genmab Profit Drops In Q3, Maintains FY26 Revenue Outlook RTTNews · 5 days ago
- Genmab A Consensus Price Target Raised 32.78% to $56.10Fintel · Nov 2, 2026
- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals RTTNews · Oct 30, 2026
- Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer LaunchesMarketBeat · Oct 28, 2026
- Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30% RTTNews · Oct 28, 2026
- Genmab's Petosemtamab Combination Improves Survival In Phase 3 Head And Neck Cancer Trial; Stock Up RTTNews · Oct 28, 2026
The company
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- genmab.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.